Skip to main content
Fig. 2 | Pediatric Rheumatology

Fig. 2

From: Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment

Fig. 2

Adalimumab Trough Levels for complete responders, partial responders and non-responders after at least 24 weeks of adalimumab treatment. Boxes represent median values and the first to third quartile. The whiskers extend to the furthest observation within ± 1.5 IQR of the first and third quartile. Observations outside 3 IQR are marked with (°)

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096